Mabwell (SSE: 688062) is an innovation-driven biopharmaceutical company with an entire industry chain of R&D, manufacturing, and commercialization. Consistent with our commitment to provide more effective and accessible therapies and innovative products, Mabwell has worked to fulfill global medical needs and bring life-changing solutions to patients.
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador
Mabwell Announces the First Patient Dosed in the Clinical Studies of 2 Novel ADCs
Mabwell Partners with UNILAB to Market its Adalimumab Biosimilar in the Philippines